Edusa, Mitsubishi Tanabe Pharma deal

Mitsubishi Tanabe disclosed in its 3Q11 earnings for the year ending March 31, 2012, that it terminated a license agreement for MKC-733 (DPP733), a serotonin (5-HT3) receptor partial agonist in Phase...